Transcript: Which HIV Meds Cause Lipoatrophy?

Transcript: Beyond Condoms: Medical Approaches For Prevention

Transcript: Simple Test Eliminates Abacavir Risk

Transcript: Are We Starting Treatment Early Enough?

Transcript: The Latest on Lipo: Advances & Setbacks

Prezista Superior to Kaletra for Treatment-Experienced Patients
Preliminary results from a major clinical trial have demonstrated that Prezista plus Norvir is more effective than Kaletra in treatment-experienced HIV-positive patients.

NNRTI Etravirine Effective for Treatment-Experienced Patients
Studies reviewed at the fourth IAS Conference in Sydney indicate that Tibotec's NNRTI etravirine, combined with the company's PI Prezista, is safe and effective for treatment-experienced HIV-positive patients.

PRO 140 Shows Promise in Single-Dose Study
Researchers have reported encouraging results from an early study of PRO 140, an experimental HIV entry inhibitor.

Lady Gaga Supports HIV-Positive Youth in England

Ryan White’s Mom Remembers Michael Jackson

WHO: TB Vaccination Fatal for Babies With HIV

Post-Menopausal Women Do Well on HIV Therapy
Women living with HIV who’ve gone through menopause do just as well when starting antiretroviral (ARV) therapy for the first time, compared with pre-menopausal women, according to a study published online June 25 in Clinical Infectious Diseases.

Unexpected Finding: Penetration of ARVs Into Nervous System Doesn’t Protect the Brain
While antiretroviral (ARV) drugs known to penetrate into the cerebrospinal fluid (CSF)—and thus possibly the brain—do lower HIV levels in the brain, they do not appear to protect against detrimental changes in thinking, memory and physical coordination. This is the conclusion of a study published in the July 17 issue of AIDS.

HIV and ARV Therapy Accelerate Bone Loss
Bone loss is common among people living with HIV before they begin antiretroviral (ARV) therapy, and it worsens upon starting treatment, especially if the regimen contains Combivir, according to a new report published in the July 17 issue of AIDS.

High Percentage of U.S. Residents Receiving Late HIV Diagnoses
Forty-five percent of people newly diagnosed with HIV infection in the United States progress to AIDS within three years, according to new data published by the U.S. Centers for Disease Control and Prevention in the June 26 issue of Morbidity and Mortality Weekly Report. The findings suggest that many people are being diagnosed late in the course of their HIV infection; the findings also underscore, according to the CDC authors, the need for expanded testing efforts in order to link people to necessary care as soon as possible.

Improving Survival From Non-Hodgkin’s Lymphoma
Survival among people with HIV who are diagnosed with non-Hodgkin’s lymphoma (NHL) continues to improve, according to an encouraging reported published online June 15 in AIDS. The study found two thirds of people diagnosed with the cancer survived at least one year after diagnosis.

Second-Line Treatment for PCP a Viable Alternative
Neutrexin (trimetrexate) combined with Leucovorin (folinic acid) is an effective and safe treatment option for people who don’t respond to their first treatment regimen for Pneumocystis pneumonia (PCP), according to a study published in the June 19 issue of AIDS.

Pomp, Circumstance and a Second Chance
Housing Works’s Second Life Job Training Program prepares HIV-positive, low-income New Yorkers to re-enter the workforce.